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SCC in-situ (SCCIS), or Bowen’s disease, is a precursor to invasive squamous 
cell carcinoma (SCC) of the skin. Compared to other available treatment modalities, 
photodynamic therapy (PDT) may offer comparable efficacy with decreased morbidity 
and better cosmetic and functional outcomes. This retrospective study analyzes the 
effectiveness and outcomes of photodynamic therapy with aminolevulinic acid (ALA-
PDT) treatment of cutaneous squamous cell carcinoma in-situ (SCCIS) with blue light. 
Data collection and statistical analysis was performed on the demographics, clinical 
history, and procedure details of patients who have biopsy-confirmed diagnoses of 
SCCIS treated initially with PDT. Treated lesions had a complete response rate of 55% 
(39/71) after initial PDT treatment. 83% (52/63) of lesions had a complete response with 
1-2 cycles of PDT. Age and large size (>2 cm) were inversely correlated with complete 
initial response. The mean disease-free survival was 13.379 months (standard deviation 
of 2.0 months, C.I. [9.477, 17.280], 41 observations) for lesions receiving 1 PDT 
treatment, and 13.590 months (standard deviation of 2.3 months, C.I. [9.072, 18.107], 23 
observations) for lesions receiving 2 treatments. There was no statistical difference 
between 1 and 2 PDT treatments in terms of disease-free survival function. Recurrence 
rates were 12% (4/33) following 1 PDT treatment and 32% (6/19) following 2 PDT 




SCCIS and skin cancers arise when cancer-causing mutations develop and 
accumulate in keratinocytes. The majority of skin cancer cases are attributed to mutations 
caused by ultraviolet (UV) radiation. Specific UV-induced mutations in tumor-suppressor 
genes have been documented in normal skin, skin cancer precursors, and SCC lesions. 
This study aims to develop a system to quantify and characterize the mutations in TP53, 
Hras, Nras, Kras, CDKN2a, Notch1, Notch2, Notch3, Fat1, Fgfr3, Knstrn, and Braf in 
clinically and histologically normal skin, and relate this data to level of sun damage using 
next-generation sequencing. This project is still in process. At this point, primers have 
been designed to be used in concert with Illumina, Inc.’s extension-ligation system to 
target a total of 59,547bp within the aforementioned genes, and sequencing of an initial 
cohort of patient samples has been completed with a total sequence size of 1.54E11bp 
with 72.26% high-quality sequence. Ongoing work of sequence analysis will quantify the 
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Skin cancer is the most commonly diagnosed cancer in the United States[1] and the 
most common malignancy worldwide[2, 3]. The incidence of both non-melanoma skin 
cancer (NMSC) and melanoma is increasing[1]. 99% of NMSC cases are basal cell 
carcinoma (BCC) or cutaneous squamous cell carcinoma (SCC).[4] One set of estimates 
is that the total number of NMSCs in the US population in 2012 at 5,434,193 and the 
total number of persons in the United States treated for NMSC at 3,315,554, with a BCC 
to SCC incidence ratio of approximately 1 based on the Medicare fee-for-service 
population.[5] In contrast, previous studies and multiple previous sources have reported 
that BCC is the most common type of NMSC and occurs at an approximately 4:1 ratio to 
SCC incidence. [6] A different sources states the average annual number of adults treated 
for skin cancer increased from 3.4 million in 2002-2006 to 4.9 million in 2007-2011 
(p<0.001). During this period, the average annual total cost for skin cancer increased 
from $3.6 billion to $8.1 billion (p=0.001), representing an increase of 126.2%, while the 
average annual total cost for all other cancers increased by 25.1%. During 2007-2011, 
nearly 5 million adults were treated for skin cancer annually, with average treatment costs 
of $8.1 billion each year. [1] 
 Since risk of skin cancer correlates with increasing age, the aging baby boomer 




Cutaneous squamous cell carcinoma (SCC) is the second most common type of 
skin cancer. Its incidence among the US Medicare fee-for-service population in 2012 is 
estimated to be 1,027,700, and while both BCC and SCC are increasing in incidence, 
SCC rates may be increasing at a faster rate than BCC.[5] A study of South Florida 
patients treated in 1996 for NMSC yielded a higher prevalence of SCC than BCC,[7] and 
a survey of Mohs fellowship directors showed an increasing ratio of SCC to BCC treated 
by Mohs.[8]  
Environmental risk factors for skin cancer include exposure to ultraviolet (UV) 
radiation, chemical exposures, immunosuppression, immunocompromised conditions, 
chronic skin injury or irritation, and human papillomavirus (HPV) infection. Genus β 
human papillomavirus infection has been associated with SCC but not BCC.[9] NMSC is 
associated with chemical exposures to “pesticides, asphalt, tar and polycyclic aromatic 
hydrocarbons, and they typically result in SCC”. [10] Arsenic is associated with both 
SCC and BCC. [11] Immunosuppression, such as in organ transplant recipients, and 
immunocompromised states, such as HIV infection, are also associated with increased 
risk of skin cancer, especially SCC, and the majority of SCCs in organ transplant 
recipients were found to contain HPV DNA[10]. Ionizing radiation has been implicated 
in SCC pathogenesis, which also means increased risk for airline pilots and other 
occupations involving increased exposure to ionizing radiation.[10] 
UV radiation is the best known environmental risk factor for skin cancer, and in 
the northern hemisphere, decreasing latitude consistently correlates with increasing rates 
of skin cancer. [10] (Intensity of UV radiation generally increases as one gets closer to 




long-term UV dose and cancer risk, whereas BCC risk correlates more linearly with 
number of severe sunburns. [12] In Caucasians, skin cancer also tends to develop in areas 
with large amounts of sun exposure, with the head and neck as the most common sites of 
SCC[13, 14] and over 80% of NMSCs developing on the head, neck, and hands.[15] On 
the other hand, melanoma’s most common anatomic sites vary by age group and gender, 
with melanoma occurring most commonly on the trunk in men and on the lower 
extremities followed by the trunk in women, but occurring most commonly on the head 
and neck in patients who were 80 years old or older. This may be related to cultural 
aspects of skin exposure that vary by age and gender.[15, 16] Furthermore, in the United 
States, where drivers sit on the left side of cars and therefore receive more UV radiation 
to the left side of their body, skin cancers are more likely to occur on the left than the 
right. [17] 
Given the relationship between UV radiation and skin cancer, depletion of the 
ozone layer, an atmospheric layer that absorbs the majority of UV-B radiation from the 
sun, in recent history[18] may be contributory to the rise in skin cancer incidence. 
Not only does UV radiation occur during typical outdoor activities, it can also 
occur during tanning lamp usage, therapeutic UV exposure, and occupational work like 
agriculture. Intentional tanning has been shown to increase the risk of both BCC and SCC 
[19]. Psoralen and ultraviolet A (PUVA) therapy is used to treat several skin conditions, 
such as atopic dermatitis, psoriasis, graft-versus-host disease, and vitiligo. Long-term 
PUVA therapy has been found to correlate with SCC risk in a dose-related manner. [20] 





Humans have some natural protection against UV radiation in the form of 
melanin. Melanin is a naturally-occurring pigment in multiple organs and species, 
including human skin, and is produced by specialized cells called melanocytes which 
reside in the epidermis, among other places. It is produced and contained within 
organelles called melanosomes, which are then transported to nearby keratinocytes. [21] 
Epidermal melanin provides some protection against UV-induced DNA damage by 
partially filtering out UV radiation, and since darker skin tends to have more melanocyte 
activity and larger, more dispersed, and more melanized melanosomes than lighter skin, 
dark skin is more protective against UV-induced skin damage than paler skin. [22] 
Conversely, since UV-B rays are also necessary for vitamin D synthesis, darker-skinned 
people are more at risk for vitamin D deficiency than their lighter-skinned counterparts at 
the same latitude.[23] 
Since susceptibility to UV-induced skin damage is dependent on intrinsic 
phenotypic characteristics, skin cancer, like many other cancers, has genetic risk factors 
as well. Light skin, red hair and to a lesser extent blonde hair, poor ability to tan, 
freckling, and by extension Caucasian race are well-known risk factors for both NMSC 
and melanoma.[24, 25] Certain MC1R alleles are associated with fair skin and red hair, 
which means they are also associated with increased melanoma and NMSC 
risk.[10] ”Epidermal melanin in blacks filters twice as much ultraviolet B 
(UVB) radiation as does that in Caucasians,”[26] and a greater dose of UV radiation is 
required to produce erythema in black skin than in white.[21] In Hawaii, the incidence 
proportion of ethnic Japanese who develop NMSC is much lower than the incidence 




color, tanning ability, and likelihood to develop sunburns, the Fitzpatrick skin type or 
phototype classification scheme was developed and adopted to characterize individuals’ 
skin based on these characteristics, with lower numbers corresponding to generally 
lighter skin and greater likelihood of developing sunburns instead of tanning.[28]  
Oculocutaneous albinism, an autosomal recessive condition which involves 
defective melanin synthesis, naturally also leads to an increased risk of melanoma and 
NMSC, especially SCC, compared to normal individuals.[10] 
While skin pigment helps prevent DNA damage from UV rays, DNA repair 
mechanisms guard against skin cancer by repairing DNA after receiving UV-mediated 
damage.  
UV radiation induces genetic mutations in the cells of sun-damaged skin 
primarily through the process of generating pyrimidine dimers in DNA, and to a lesser 
extent double-stranded breaks. Left uncorrected, these changes can be mutagenic or 
carcinogenic by leading to errors in DNA replication and transcription. However, 
numerous DNA repair mechanisms exist to combat this. Nucleotide excision repair is the 
main repair mechanism for UV-mediated damage involved in mammals, wherein 
thymine dimers are removed and then replaced on the DNA strand by polymerase and 
ligase.[29] In plants and some other organisms, photolyases can repair pyrimidine 
dimerization by harnessing the power of light to directly break intradimer bonds.[30] 
However, in an autosomal recessive condition known as xeroderma pigmentosum, 
affected individuals have defective nucleotide excision repair enzymes. As a result, 




increase in rates of melanoma, BCC, and SCC compared to the general US 
population.[31] 
Other genetic conditions that lead to an increased risk of skin cancer include 
dystrophic epidermolysis bullosa, which involves mutations in type VII collagen and is 
associated with SCC; Gorlin syndrome, also known as nevoid basal cell carcinoma 
syndrome, which involves a PTCH mutation and, as the name suggests, BCC; Bazex 
syndrome, which is associated with BCC; and Rombo syndrome, which is associated 
with BCC. Epidermodysplasia verruciformis is a rare inherited disorder that involves 
widespread cutaneous HPV colonization and an increased risk of SCC. [10] 
Given their decreased susceptibility to UV-induced skin damage, the 
epidemiology of skin cancer in darker-skinned individuals is quite different. Instead of 
exposure to UV radiation, the most significant risk factor for SCC may in fact be chronic 
skin irritation and injury. [10] However, UV radiation still has an impact on skin cancer 
risk in individuals of color. Given differences in UV intensity and outdoor activities, 
people of Japanese ethnicity in Japan and Hawaii exhibit different rates of skin 
cancer.[32] UV radiation exposure has also been shown to have a significant effect on 
BCC risk in blacks. [26, 33]  
 
Actinic keratosis and squamous cell carcinoma in-situ 
 Precursors to SCC include actinic keratosis and squamous cell carcinoma in-situ 
(SCCIS), also known as Bowen’s disease (BD). 
 Actinic keratosis (AK) is a premalignant lesion containing atypical keratinocytes 




transform into SCC.[10] The risk of AK evolving into SCC is estimated to be 0.075–
0.096% per lesion per year.[10] Since the risk factors for AK are shared with risk factors 
for skin cancer, they can serve as markers for a high risk of developing SCC.[34] About 
12% of Americans are estimated to have actinic keratoses.[35] Clinically, they tend to 
present as scaly erythematous papules varying in size.[10] 
 Squamous cell carcinoma in-situ (SCCIS), also known as Bowen’s disease (BD), 
is a precursor to invasive SCC and refers to SCC that is confined to the epidermis.[36] 
Clinically, it can present as an erythematous plaque or patch with scale.[10, 36] SCCIS 
lesions are thought to have a 3-5% risk of progression to invasive SCC.[37] Treatment 
options for SCCIS include simple excisional surgery, Mohs surgery, cryotherapy, 
imiquimod, 5-fluorouracil, electrodessication and curettage, and photodynamic therapy 
(PDT).[36-38] Surgery has been reported to have low recurrence rates of 4.6%-8.3%.[39-
42] Imiquimod, a topical immune response modifier, has been reported to have complete 
response rates of 93%[43] and 75%.[44] In the randomized controlled trial demonstrating 
75% complete response, no recurrences occurred within the 9mo follow-up.[44] 
Fluorouracil, also known as 5-FU, is another topical treatment and has reported complete 
response rates of up to 92%[43] and 67%[45]. 
 
Tumorigenesis and Field Cancerization 
 During tumorigenesis, driver mutations in oncogenes accumulate, which leads to 
expansion of mutated clones and positive selection for clones with more malignant 
potential.[46, 47] These driver genes confer a selective advantage to the cells that have 




in normal non-cancerous cells must be occurring in order for the accumulation of cancer-
promoting mutations and malignant transformation to be possible.[48] Leukemia-
associated somatic mutations have been shown to accumulate with age in blood cells in 
individuals without overt hematological disease.[49] 
Specific mutations in tumor-suppressor genes have been documented in normal 
skin, actinic keratoses, and SCC lesions. Mutations in TP53, a tumor suppressor gene that 
plays a crucial role in the development of SCC, have been found in histologically and 
clinically normal skin[50, 51] and actinic keratosis,[52] a precursor of SCC. Up to 4% of 
normal skin contains keratinocytes with TP53 mutations, and the mutation burden 
corresponds to actinic damage.[50] A high burden of Notch1, FAT1, Kras, Nras, and 
Hras mutations associated with skin cancer has also been found to exist in normal sun-
exposed skin, and normal keratinocytes undergo pervasive positive selection for these 
mutations.[51] As part of the phenomenon known as “field cancerization,”[53] lesions of 
SCC are then more likely to develop in these “fields” of genetically-altered skin.[54] 
Several mutations have been characterized in SCC, including functionally 
significant mutations in the tumor suppressor genes TP53, Notch1, Notch2, and 
CDKN2A.[55-57] SCC lesions have been reported to have mutation burdens of 63-95% 
in TP53,[56, 57] 82% in Notch1 and/or Notch2,[57] and 28% in CDKN2A. [57] 
TP53, for instance, is a tumor suppressor gene nicknamed “the guardian of the 
genome” which plays multiple critical roles inside the cell when DNA damage is 
incurred. [58] As a tumor suppressor gene, loss-of-function (LOF) mutations of TP53 is 
generally associated with cancer, in contrast with oncogenes, where gain-of-function 




chromosome 17 at 17p13.1 in humans. The gene is 19,149bp long with 11 exons, and is 
highly conserved across multiple species. [60, 61] p53, the protein encoded by TP53, is 
activated in response to DNA damage, oxidative stress, or other forms of cytotoxic 
stress.[62] 
TP53 mutations have been implicated in multiple cancers, such as cutaneous SCC, BCC, 
melanoma, colon, lung, esophagus, breast, liver, brain, reticuloendothelial tissues, and 
hematopoietic malignancies.[63] Most functional TP53 mutations occur in the DNA-
binding domain, which affects p53’s ability to activate downstream genes and induce cell 
cycle arrest or apoptosis.[62] Without proper p53 function, cellular mutations can rapidly 
accumulate without cell cycle arrest, which can ultimately lead to uncontrolled 
proliferation if the right set of mutations occur. This phenomenon occurs in Li-Fraumeni 
syndrome, a hereditary predisposition to cancer, including melanoma, involving 
autosomal dominant inheritance of a mutated TP53 allele.[64]  
Mutated keratinocytes in a field of damage appear to be precursors to SCC and 
SCC in situ. Many patients develop multiple primary lesions within the same field. Field 
treatment like PDT targets both the cancer and the surrounding field, so theoretically 
PDT may be more effective at preventing subsequent cancers than lesion-based therapy, 
such as surgery.  
Although there is scientific awareness that field cancerization exists, laboratory-
based methods of quantifying the mutation severity or the cancer risk of a field of skin, or 
of tracking response to therapy, do not exist for clinical use. Mutation burden analysis 





Photodynamic Therapy (PDT) 
 Photodynamic therapy (PDT) is a treatment comprised of three necessary 
components: a photosensitizer, visible light, and oxygen, allowing for the generation of 
reactive oxygen species. The therapy involves two distinct stages: the first stage is 
application of the photosensitizer in the absence of light, and the second stage is the 
application of light. It has been utilized in a large number of dermatologic and oncologic 
conditions and in various anatomic sites, including skin conditions such as psoriasis, 
actinic keratosis, squamous cell carcinoma in-situ, basal cell carcinomas, as well as for 
cosmetic purposes; tumors of the oral cavity, pharynx, and larynx; Barrett’s esophagus; 
cholangiocarcinoma; peritoneal carcinomatosis or sarcomatosis; prostate cancer; bladder 
cancer; and non-small cell lung cancer (NSCLC). [65, 66] 
 The use of light therapy dates back to the ancient Egyptians, who would treat 
vitiligo with sunlight and the oral ingestion of a plant that contained psoralen, a 
compound still used in modern medicine in combination with UV light to treat a variety 
of dermatologic conditions.[67] The history of contemporary phototherapy starts with 
Finsen using filtered light from a carbon-arc lamp to treat lupus vulgaris, a skin infection 
with M. tuberculosis, for which he was later awarded the Nobel Prize in Physiology or 
Medicine in 1903.[68] Shortly after, a German team discovered that acridine was a 
photosensitizer and coined the term “photodynamic effect,” which they later used to treat 
solid tumors in one of the first applications of photodynamic therapy to cancer. [69-72] 
 Photodynamic therapy fell out of favor until Dougherty started clinical trials of 
PDT with hematoporphyrin derivative (HPD), a combination of porphyrins, as the 




adenocarcinoma, prostate cancer, mycosis fungoides, endometrial carcinoma, breast 
cancer, angiosarcoma, or SCC in 1978. The trial was successful and resulted in a 
commercially available photosensitizer. [69, 73] HPD was given the brand name 
Photofrin, and was “first given approval in 1993 by the Canadian health agency for use 
against bladder cancer.”[74] Approval in more countries and for usage against more 
cancers quickly followed.[74] Even today, Photofrin is the most widely-used 
photosensitizer.[65] 
 The next major breakthrough in PDT research was the discovery that 5-
aminolevulanic acid (ALA or 5-ALA) was a precursor of protoporphyrin IX (PPIX),[65] 
which opened the door for second-generation photosensitizers. In the heme biosynthetic 
pathway, ALA can be converted to PPIX and then ultimately heme. Normally, excess 
heme then provides negative feedback by inhibiting ALA synthase, the enzyme that 
synthesizes ALA, to prevent the accumulation of protoporphyrin and other intermediates. 
However, the addition of exogenous ALA bypasses this step, which then leads to an 
accumulation of PPIX within the cell because the final enzyme in the pathway, 
ferrochelatase, is rate-limiting.[66] In ALA-PDT, the pro-drug ALA is administered to 
patients and then converted to the photosensitizer PPIX by the patient’s own cells. 
 Methyl aminolevulinate (MAL) is an esterified and therefore more lipophilic form 
of ALA, which allows topical MAL to penetrate skin more readily than ALA and achieve 
a higher intracellular concentration of PPIX.[75] It is used to treat similar conditions as 





 Photosensitizers such as PPIX are molecules that can absorb units of light energy, 
or photons, at specific wavelengths and then utilize this energy to undergo reactions with 
other molecules to eventually generate reactive oxygen species (ROS) and radicals, 
which then can inflict cellular damage. [74] 
 After absorption of a photon, the photosensitizer is excited to a singlet state, and 
then can rapidly transition directly to the ground state or drop to a less excited triplet state 
before dropping back to the ground state. Prior to returning to the ground state, the 
photosensitizer can generate phototoxicity through two different types of processes. In 
Type I processes, the photosensitizer, in its singlet or triplet state, interacts directly with a 
substrate via a reduction-oxidation (redox) reaction to generate a free radical (also known 
as “radical”), which can then interact with molecular oxygen to generate various reactive 
oxygen species (ROS). In Type II, the excited triplet photosensitizer directly undergoes a 
redox reaction with molecular oxygen to generate ROS. The Type II process 
predominates in the use of photodynamic therapy to generate cellular damage, although it 
is possible for both pathways to be at play in PDT. [74] 
 The ideal characteristics of a photosensitizer will vary depending on the context 
and therapeutic intent, but there are properties that are endorsed by multiple, although not 
necessarily all, sources: 
1. Strong absorption in the visible or infra-red spectrum. Light at these 
wavelengths is readily available and has no tissue toxicity. Longer wavelengths in the 
600-800 or 600-850nm range (red to deep or infra-red spectrum) may be superior for 
some applications.[65, 74] Light at these wavelengths can penetrate deeper into 




light for PDT, so it may be less relevant if another wavelength is being used and the main 
characteristic desired is for strong absorption in the relevant wavelength. However, light 
at longer wavelengths will likely not generate enough energy for the photochemical 
reaction.[65] 
2. Have minimal dark toxicity. In other words, the ideal photosensitizer should 
not exhibit cytotoxicity in the absence of light.[65, 74] This allows the provider to have 
greater control over the effects of PDT by manipulating the amount and type of light 
provided. 
3. Rapidly clear from the body. This should help decrease cytotoxicity. For 
instance, one of the most common adverse effects of PDT is photosensitivity in normal 
tissue, so rapid clearance could help reduce patient discomfort or inconvenience.[69] 
4. For practical purposes in terms of production and clinical availability, ideally 
the photosensitizer would be a) a single well-characterized compound that b) has a simple 
or reliable means of production and c) a stable and reproducible formulation.[69, 74] 
Additionally, “The drug itself should be easily shipped and transported in a stable state 
and if needed to be reconstituted, this process should be possible by trained pharmacists 
without the requirement of specialized laboratories or tools. The administration of the 
drug itself should be possible in an outpatient setting.”[69] 
5. Selectively target or preferentially accumulate in diseased tissue over normal 
healthy tissue. [69, 74] During the topical application of ALA-PDT to treat neoplastic 
skin lesions, ALA may more readily penetrate tumor cells due to a disrupted stratum 
corneum, but this is not the main reason for its selective effect.[75, 76] Neoplastic cells 




which synthesizes a precursor of PPIX, and decreased ferrochelatase activity, which 
means PPIX accumulates more rapidly in diseased skin than normal skin.[75, 77, 78] 
6.  Be deliverable to the target tissue. One author suggests solubility in biological 
media for intravenous (IV) delivery,[74] while another suggests amphilicity- the dual 
properties of hydrophilicity for delivery through the bloodstream and lipophilicity to 
enter the tumor.[69] In the case of topical PDT for malignant or pre-malignant lesions, 
ALA’s molecular size is small enough to allow penetration of the skin, and an esterified 
form of ALA, called methyl-aminolevulinate (MAL), has increased lipophilicity so it can 
penetrate deeper into the skin.[66] 
7. Efficiently undergo the photodynamic reaction and efficiently generate 
ROS.[69, 74] Since the length of time spent in the triplet state affects the ability of the 
photosensitizer to generate ROS or interact with substrate, then longer durations of the 
triplet state are desirable.[74] 
 The majority of photosensitizers currently used in PDT have a cyclic tetrapyrrole 
or derivative structure. While other kinds of photosensitizers, such as methylene blue, 
acridine, and rose bengal, also exist, photosensitizers with a cyclic tetrapyrrole structure 
are used more predominantly in modern times because their structure is similar to 
endogenous porphyrins and therefore have low dark toxicity.[74] These second-
generation photosensitizers include MAL, ALA, benzoporphyrin derivative monoacid 
ring A (BPD-MA), chlorins, bacteriochlorins, expanded porphyrins, and phthalocyanine 
derivatives. Further work is underway to develop third-generation photosensitizers 




 The other important controllable component of the procedure is the light source. 
For electromagnetic radiation, which includes visible light, wavelength is inversely 
correlated with frequency, and since the Planck-Einstein relation states that the energy of 
a photon is directly correlated with its frequency, then photon energy is inversely related 
to wavelength. Above around 800nm, illumination is ineffective for PDT because it does 
not provide sufficient energy to excite the photosensitizer.[65] Since electrons can only 
absorb defined quantities of energy to reach an excited state, compounds will have 
absorption peaks at certain wavelengths. PPIX has a maximal absorption peak in the blue 
range at around 405nm[79] or 410nm[80] called the Soret band. It also has smaller 
absorption peaks in the visible range, called Q bands, at 505 or 510nm (green), 540nm, 
575 or 580nm, and 635nm (red) wavelengths,[69, 80, 81] ROS are generated more 
rapidly at shorter wavelengths, which allows for shorter treatment times.[69] On the flip 
side, longer wavelengths of light are able to penetrate tissues more deeply, and the 
“optical window of tissue” is often considered 600nm-1200nm, which ranges from the 
red to near-infrared portions of the electromagnetic spectrum.[65] The skin’s superficial 
nature is advantageous when it comes to PDT, since it means that light penetration is less 
of a concern than it may be for other bodily tissues and using shorter-wavelength higher-
energy forms of light is feasible.  
 ALA-PDT and MAL-PDT have been used for the treatment of NMSC and other 
dermatological conditions. One of the earliest clinical trials involving ALA-PDT was a 
clinical trial in the early 1990s using 3-6hour incubation and 3.5 to 30min light exposure. 
Preliminary results from that clinical trial showed a complete response at the 2-3month 




SCC or SCCIS, and 9/10 AKs. 2 SCC lesions that were raised ³10mm above the surface 
of the skin were unresponsive to multiple treatments, and PDT had limited usefulness in 
treating the percutaneous nodules of 4 cases of metastatic breast cancer. [82] Another 
1993 study using ALA-PDT with 4-8 hour incubation “observed a complete response 
after a single treatment for all 9 solar keratoses, 5 of 6 early invasive squamous cell 
carcinomas, and 36 of 37 superficial basal cell carcinomas. Only 1 of 10 nodulo-
ulcerative basal cell carcinomas completely resolved. Eight cutaneous metastases of 
malignant melanoma were therapeutic failures.”[83] 
 Both MAL-PDT and ALA-PDT are frequently used to treat actinic keratosis, and 
have been shown to have comparable results to other treatment modalities. Multiple 
randomized controlled trials have shown that both ALA-PDT and MAL-PDT have 
superior results compared to controls using a vehicle and light, with rates of complete 
response of greater than or equal to 70%.[84-86] Several trials also show that MAL-PDT 
can achieve similar treatment success rates as cryotherapy and 5-fluoruracil (5-FU) 
treatment. Depending on the study, PDT had complete response rates of 69-91% 
compared to complete response rates of 68-75% for cryotherapy, and when cosmetic 
outcomes and patient comfort were examined, PDT consistently performed superiorly to 
cryotherapy.[85, 87] One study that measured % reduction in lesional size instead of 
complete response rate had 70% reduction in lesional area for 5-FU treatment and 73% 
mean reduction in lesional area for PDT treatment.[88] 
 The results from a 1991-1992 phase I clinical trial using ALA-PDT to treat 
SCCIS, superficial BCC, and metastatic skin lesions from breast adenocarcinoma or SCC 




response rate of 89% in 36 cases of SCCIS, 50% complete response in superficial BCC, 
and poor treatment response in metastatic lesions.[89] 
 In the US, ALA, under the brand name Levulan, gained FDA approval for the 
treatment of AKs in Dec. 1999. [90] 
 PDT has also been used and studied in the treatment of BCC multiple times, and it 
can be an effective treatment against BCC.[91, 92] Compared to simple excision surgery, 
MAL-PDT does not have a statistically significant difference in complete response rates 
when treating superficial BCC, with complete response rates of 92.2% (118/128 lesions) 
after 1-2 treatments of PDT compared to 99.2% (117/118 lesions) for surgery. However, 
PDT performed significantly better in terms of cosmetic outcome.[93] In another study 
comparing PDT and surgery for nodular BCC, ALA-PDT and simple excision surgery 
had similar response rates of 94% (78/83) and 98% (86/88) respectively, but PDT had 
significantly higher recurrence rates within the first 3 years at 30.3% versus 2.3% 
respectively.[94] A 2012 study also found that ALA-PDT had statistically similar 
response rates and recurrence rates as surgery but superior cosmetic outcomes.[95] 
Compared to cryotherapy, PDT also has similar response rates, but it had 5% instead of 
13% clinically obvious recurrences and performed significantly better in terms of 
cosmetic outcome.[96] In contrast, a different study found that for superficial BCC, 
imiquimod and 5-FU were more effective treatments than MAL-PDT.[97] 
 In contrast to BCC, PDT has been used much fewer times as a curative treatment 
for SCC, likely because SCC is more aggressive than BCC. Several cases have been 




response rates for SCC, one with 54% (19/35) complete response rate[100] and another 
with 25% (1/4) complete response rate.[81] 
 Since surgery performs as well or better than PDT in terms of efficacy when 
treating cutaneous malignancies, PDT may be preferable in cases where cosmetic 
outcome is particularly important, such as when the lesion size is large or the lesion is in 
an aesthetically sensitive area, in patients who are poor surgical candidates, when lesion 
size or location are contraindications to surgery, or when patient preference dictates that 
PDT is attempted first. 
 
Treatment of Cutaneous Squamous Cell Carcinoma In-Situ with PDT 
 Although PDT is not FDA-approved for the treatment for SCCIS, several studies 
and case reports have been published about using PDT to treat SCCIS. Multiple treatment 
protocols exist, so studies and clinical treatments may use a variety of incubation times 
and light sources. A case report was published in 2000 in which ALA-PDT with 4-hour 
incubation with 20% ALA and red and near-infrared light successfully treated SCCIS on 
chronic radiation dermatitis and no recurrence was observed in 18 months of follow-
up.[101] Then in 2001, a case series was published with 16 hour incubations with 2% 
ALA and “a newly designed light-emitting diode (LED) array with a peak wavelength of 
630 nm,” which is red light. The cases involved the treatment of SCCIS of the digit in 4 
patients with chronic arsenicism, which resulted in 1 recurrence within the first 15-17mo 
following treatment.[102] The major risk factor for SCCIS in both these cases differs 




The largest randomized controlled trial of PDT for the treatment of SCCIS 
compared MAL-PDT to 5-fluorouracil treatment and cryotherapy, as well as placebo 
PDT. The light source used was 570-670 nm (red light), and incubation was 3 hours with 
160mg/g MAL. “The clinically verified complete response rate of lesions 3 months after 
last treatment was 93% (103/111) in the methyl aminolevulinate PDT group, 21% (4/19) 
in the placebo PDT group, 86% (73/85) in the cryotherapy group, and 83% (24/29) in the 
fluorouracil group.” Complete response rates at 12mo were not significantly different 
between PDT and 5-FU treatment, but cryotherapy performed significantly worse. 
“Lesion recurrence rates 12 months after the last treatment were 15% (15/103) in the 
methyl aminolevulinate PDT group, 50% (2/4) in the placebo PDT group, 21% (15/73) in 
the cryotherapy group, and 17% (4/24) in the fluorouracil group.” “Cosmetic outcome 
(on-site evaluation) at 3 months was clearly superior with methyl aminolevulinate PDT 
compared with either cryotherapy or fluorouracil, with a good or excellent outcome in 
94% (77/82) (95% CI, 86%-98%) of patients treated with methyl aminolevulinate PDT vs 
66% (43/65) (95% CI, 53%-77%) treated with cryotherapy and 76% (16/21) (95% CI, 
53%-92%) treated with fluorouracil; and this was maintained for 12 months.”[103] 
In 2007, a group in the Netherlands compared single illumination PDT, which is a 
typical single PDT treatment, against double-illumination PDT, wherein a lesion would 
be illuminated with 630 nm (red) light once at 4 hours after ALA application and once 
again at 6 hours after ALA application. Incubation utilized 20% ALA and lasted 4 hours. 
25 lesions were assigned to each of the two treatment groups. Ultimately, the study found 




(22/25) as opposed to 80% (20/25), but this difference was not statistically 
significant.[104] 
  In 2008, a series of cases from Shanghai Skin Diseases & STD Hospital was 
published detailing their use of PDT for several conditions, including 13 cases of SCCIS. 
Their treatment procedures varied between cases, with 3-5 hour incubations with 20% or 
10% ALA, 635nm light, and 3-5 treatments for all patients. 92.3% (12/13) of the SCCIS 
cases showed a complete response, and no SCCIS recurrences were reported in 12mo of 
follow-up.[99] 
 In 2009, a study was published looking at long-term follow-up in 19 cases of 
SCCIS. While the previous studies mentioned had follow-up lengths of around 18mo or 
less, this study followed patients for an impressive 60mo after treatment. Lesions were 
treated with 6hour 20% ALA incubation, 630nm (red) light, and 1 treatment session, and 
the therapy yielded 89.5% (17/19) tumor-free survival at 3mo and 53.3% (8/15) tumor-
free survival at 60mo post-treatment.[105] 
 This was followed in 2011 by another study looking at long-term follow-up in 
PDT for SCCIS. 30 Caucasian patients with 43 lesions received 2 sessions of MAL-PDT 
1 week apart, with 3 hour incubations with 160mg/g MAL and 635nm (red) light 
illumination. Lesions had 100% (43/43) complete response at the 6mo follow-up, and 
there was 11.6% (5/43) recurrence rate with a mean follow-up length of 50 months. Of 
the 5 recurrences, 2 of them occurred in immunosuppressed patients.[106] 
 In 2012, a case series of 51 SCCIS lesions treated by MAL-PDT was published. 
Incubation lasted 3 hours and used 160mg/g MAL, followed by illumination with 630nm 




not seen for a post-treatment evaluation. 12% (6/51) of treated lesions had a recurrence, 
with a mean follow-up time of 17 months from biopsy acquisition.[107] 
 A 2015 study included 31 SCCIS lesions treated with MAL-PDT. The treatment 
protocol involved incubation for at least 3 hours with 160mg/g MAL, illumination with 
630nm (red) light, and 2 treatments spaced 1 week apart. At 3months post-treatment, 
84% (26/31) treated SCCIS lesions exhibited a complete response. However, 53.8% 
(14/26) ended up having a recurrence within a median follow-up time of 43.5 months, 
with a 5-year estimated recurrence rate of 72%.[108] 
 In 2016, a retrospective study was published comparing the efficacy of MAL-
PDT versus ALA-PDT for SCCIS, as well as BCC and AK. Incubation lasted 3 hours and 
either involved 20% ALA or 160mg/g MAL, followed by illumination with 630nm (red) 
light. If 2 PDT treatments were given, then the second treatment generally followed 
within a few weeks of the first. For SCCIS, 6 lesions received 1 session of ALA-PDT 
with a complete response rate of 83% (5/6), 3 received 2 sessions of ALA-PDT with a 
complete response rate of 100% (3/3), 4 received 1 session of MAL-PDT with a complete 
response rate of 75% (3/4), and 14 received 2 sessions of MAL-PDT with a complete 
response rate of 79% (11/14). Overall, complete response rate for SCCIS lesions treated 
with ALA-PDT was 89% (8/9) and complete response rate for SCCIS lesions treated with 
MAL-PDT was 78% (14/18). The difference between MAL-PDT and ALA-PDT was not 
statistically significant.[109] 
 All of these studies use red light illumination, even though MAL and ALA have 
multiple absorption peaks, and incubation times last at least 3 hours but can be overnight 




the number of treatments varies. Reported complete response rates are good, ranging 
from 75% to 100%, although most studies had small sample sizes. However, long-term 
recurrence rates may also be high. The studies that looked specifically at long-term 
recurrence rates had average follow-up lengths of 43.5-60 months, with recurrence rates 
of 11.6%, 54%, and 57%.[105, 106, 108] The rest of the studies described had average 
follow-up lengths of 12-24 months. Cosmetic outcome appears to be very good with 
PDT, which could be a reason to choose it as initial therapy despite suboptimal response 





STATEMENT OF PURPOSE 
 
Photodynamic Therapy for Cutaneous Squamous Cell Carcinoma In-Situ 
HYPOTHESIS 
1) blue light ALA-PDT has a high complete response rate in the treatment of SCCIS 
2) blue light ALA-PDT has a low recurrence rate or long disease-free survival interval in 
the treatment of SCCIS 
 
SPECIFIC AIMS 
1. Characterization of the clinical response rate of SCCIS lesions treated with blue light 
ALA-PDT and the relationship with factor variables including patient characteristics, 
lesion characteristics, and treatment procedure 
2. Characterization of the recurrence rate of SCCIS lesions treated with blue light ALA-
PDT 
a. Characterization of documented disease-free survival within the treatment field 
of SCCIS lesions treated with PDT 
 b. Calculation of a Kaplan-Meier survival distribution function 
c. Comparison of disease-free survival between lesions receiving different 
numbers of PDT treatments 
3. Determining the relationship between side-effects of PDT treatment and independent 





Mutation Burden Analysis 
HYPOTHESIS 
1) mutations in critical tumor-suppressor genes, namely TP53, Hras, Nras, Kras, 
CDKN2a, Notch1, Notch2, Notch3, Fat1, Fgfr3, Knstrn, Braf, exist in sun-damaged but 
clinically and histologically normal skin 




1. Develop a sequencing strategy to detect rare somatic mutations in normal skin 
a. Detection of recurrent mutations in normal skin which correlate with previously 
described TP53, Hras, Nras, Kras, CDKN2a, Notch1, Notch2, Notch3, Fat1, 
Fgfr3, Knstrn, and Braf mutations in skin cancer 
2. Comparison of mutation burden in TP53, Hras, Nras, Kras, CDKN2a, Notch1, Notch2, 
Notch3, Fat1, Fgfr3, Knstrn, and Braf with clinical degree of sun damage and other 
patient variables. 
a. Comparison of mutations in each individual gene and the composite mutation 
level in all 12 genes 
b. Analysis of mutation burden in relation to patient variables such as age, gender, 
biopsy site, and history of prior skin cancer (including both type and number of 







Photodynamic Therapy for Cutaneous Squamous Cell Carcinoma In-Situ 
 
 This was a retrospective study based on patients who had received PDT at Yale 
Dermatologic Surgery between 09/2013 to 03/2017 for a biopsy-confirmed diagnosis of 
SCCIS. Exclusion criteria included prior definitive treatment, such as Mohs surgery and 
5-FU, for the same lesion; prior PDT for the same lesion; prior PDT in the same area as 
the lesion within the past year; and lack of any follow-up visits after PDT. 
 Prior to application of the photosensitizer, lesions were cleaned with acetone or 
isopropanol and any scale, crust, or superficial debris was removed. Crusted and keratotic 
areas were treated with curettage to the level of pinpoint bleeding. One tube of Levulan ® 
Kerastick ® (20% aminolevulinic acid HCl) for topical solution) was applied to the area of 
each lesion. The area was then either wholly or semi-occluded with a Telfa® dressing, 
Glad® Press ‘N’ Seal® wrap and an opaque covering, or TegadermTM contact bandage and 
a Telfa® dressing, or left unoccluded. The medication was then allowed to incubate while 
protected from light. After the specified incubation time, any bandages were removed. 
Appropriate eye protection was used by the patient. The area was then treated with blue 
light at a wavelength of 417nm ±5 nm using the BLU-U® Blue Light Photodynamic 
Therapy Illuminator, with total fluence of 10 J/cm2 for 1,000 seconds or 16min and 
40sec, apart from 1 patient who only received illumination for 4min due to side-effects. 
Patients were followed up as clinically appropriate. The treatments and follow-up visits 
were provided by Dr. Sean Christensen, Dr. Samuel Book, or Dr. David Leffell of the 




We used the following search strategy to identify patients with SCC in situ treated 
with PDT: Patients of Yale Dermatologic Surgery (YMG) with a diagnosis code of SCC 
in-situ and a procedure code for PDT between the dates of 09/2013 and 03-2017 
(inclusive) were initially collected by electronic database search Kasia Olszewski, an 
administrator in the Dermatology department. Chart review was subsequently performed 
by me and Dr. Christensen and only those patients with a record in Epic® of their 
diagnosis of SCC in-situ by a pathologist whose SCCIS lesion(s) were treated initially 
with ALA-PDT were included in the final study. A unique numerical identifier was 
assigned to each patient and lesion and associated with the clinical variables listed below.  
I collected de-identified data on patient age, sex, visit dates, Fitzpatrick 
phototype; SCC in-situ characteristics: date of diagnosis, clinical history, lesion 
site/location, lesion size/depth, pathology report including pathologic subtype, prior 
treatments in same anatomic area, whether photographs were taken and appearance of the 
lesion in photos; treatment history and outcomes: including treatment types and dates, 
treatment protocols (incubation time, occlusion, illumination time), treatment side-
effects, adverse effects post-treatment, results post-treatment (including lesion 
appearance post-treatment, tumor recurrence, or further treatments necessary and their 
types, dates, and results), follow-up dates and visit notes. For selected patients, 
photographic images in medical record that document tumor burden without identifying 
the patient were analyzed. Patient identifying information such as name, birthdate, 
medical record number or social security number, and address or phone number were not 




 Statistical analysis was performed by me using Microsoft Excel®, XLSTAT®, and 
Stata®.  Since patients may receive more PDT treatments long after their initial sequence 
due to a recurrence, for all analyses that required the number of PDT treatments, I used 
all PDT treatments that had been administered within a year of the previous PDT 
treatment, excluding PDT treatments that were administered after recurrence had 
occurred or after another form of treatment had been used, and referred to PDT 
treatments that fit these criteria with the phrase “consecutive treatments.” 
I used a contingency table and Fisher t-test to compare complete response rate 
between 1 consecutive PDT treatment and 2 consecutive PDT treatments. Since all 
lesions had to receive at least 1 PDT treatment according to our inclusion criteria, all 
lesions with information on response after first PDT treatment were included in the 
analysis of initial response to PDT treatment. Logistic regression was used for this 
analysis because the dependent variable was binary and the output of logistic regression 
is constrained to lie in the interval [0,1]. Lesions without follow-up data after the latest 
consecutive treatment were excluded as missing data. Missing variables were excluded 
from the regression instead of replaced with other values. 
For disease-free survival analysis, patients were grouped according to number of 
consecutive treatments. Groups had mutually exclusive patients, and whether lesions had 
a complete or incomplete response to previous treatments did not matter for the survival 
analysis—only the lesion field’s status after the latest treatment that met all above criteria 
did.  
Disease recurrence or persistent disease were scored as event occurrences on the 




medical record. Disease recurrence referred to documented disease after a documented 
complete response to treatment, whereas persistent disease did not involve a documented 
complete response to treatment. Since a lesion is only at risk for recurrence if it had a 
complete response, recurrence rate was defined as number of documented recurrences 
divided by the number of lesions that had had a complete response. If a lesion did not 
have a complete response to treatment, then for the survival analysis, it was noted as 
having an event occurrence on the date of its follow-up visit and disease-free during the 
time period between receiving PDT treatment and its follow-up visit. This holds true even 
if a lesion that had persistent disease after PDT treatment was then treated with another 
modality, such as liquid nitrogen or Mohs surgery, and exhibited a complete response to 
that treatment. 
Since PDT treats an entire field and not just a specific lesion, an occurrence of 
new SCCIS within the same treatment field, even if it was not a recurrence of the 
previous SCCIS lesion, was marked as an event occurrence and equivalent to a 
recurrence for the survival analysis. Lesions that were disease-free and had no recurrence 
by the end of follow-up were labelled as censored on the last date of follow-up they were 
documented to be disease-free. 
  
Mutation Burden Analysis 
 In order to study the mutation burden of actinically damaged skin, we will be 
using the techniques of punch biopsy, DNA extraction, PCR amplification, Illumina 
TruSeq Custom Amplicon® amplification, Illumina® next-generation sequencing, and 




 First, Dr. Christensen, Dr. Book, and Dr. Leffell collected discarded patient skin 
samples obtained during their surgical treatment of skin lesions. These discarded skin 
samples were obtained from clinically normal skin adjacent to a completely excised skin 
cancer. Each sample was categorized by Dr. Christensen as to the degree of clinical 
actinic damage. 
  Next, I took multiple punch biopsies ranging in size from 1mm to 4mm from the 
areas of normal skin in the discarded biopsy samples to compare DNA yields. Initially, 
1mm punch biopsies were obtained, but based on DNA yield, subsequently 2mm punch 
biopsies were obtained.  
I performed DNA extraction on the pooled punch biopsies via the Qiagen ® 
QIAamp® kit or phenol-chloroform extraction with ethanol precipitation, then performed 
PCR amplification on the extracted DNA samples for TP53 and HRAS sequences to 
check DNA quality. We originally planned to use long-run PCR to amplify target genes, 
but this was unsuccessful. 
 The Illumina® TruSeq Custom Amplicon® system was used for library 
generation and sequencing. In this system, custom-designed oligo probes hybridize on the 
same strand to flanking regions of interest in unfragmented genomic DNA. Next, 
extension-ligation will occur between the custom probes across regions of interest. 
Unlike PCR, these amplicons would not serve as templates for subsequent rounds of 
amplification. PCR is then performed to add indices and sequencing primers to the ends 





Dr. Christensen and I designed amplicons for the exons and 5’ UTRs of TP53, 
Hras, Nras, Kras, CDKN2a, Notch1, Notch2, Notch3, Fat1, Fgfr3, Knstrn, and Braf, 
whose mutations are associated with skin cancer, and VHL as a control. We anticipate 
that we will be able to reliably detect mutations present at a frequency as low as 1% of 
the total input DNA based on the following calculation: Assuming 50% of reads are high-
quality and able to be mapped to target regions, the Illumina HiSeq2500® sequencing 
machine has the capability to sequence 300 million reads at 150bp per read. Given our 
total target size of 59,547bp, this leads to a depth of sequencing of 23,616x per bp. The 
Illumina® HiSeqXTen® sequencing machine has even greater sequencing capability at 1 
billion reads with 150bp per read, which leads to a calculated depth of sequencing of 
78,719x. 
 Next-generation DNA sequencing via the Illumina® GA/HiSeq® system will be 
performed on the amplicons using the HiSeq2500® or HiSeqXTen®. In Illumina® 
sequencing, DNA molecules from the PCR products will be bound to primers on a slide 
and amplification will be performed to produce clusters of clonal DNA fragments, which 
are then linearized into single-stranded DNA templates.[110] These multiple clusters 
allow for the massively parallel process of sequencing by synthesis, wherein 
fluorescently-labeled nucleotides (ddATP, ddGTP, ddCTP, ddTTP) are added one at a 
time to the fragments and the fluorescent signatures are simultaneously recorded.[110] 
Mei Zhong is performing the library generation and the sequencing. Software for analysis 
then matches the sequence reads against known genomic sequences.[110]  Computer-
based analysis of the DNA sequencing results will eliminate irrelevant sequences, such as 




sequence reads will be evaluated for the frequency of functionally significant mutations 
compared to silent mutations and wild-type sequences of these genes, which will then be 
analyzed for a correlation with the clinical degree of sun damage and number of prior 
skin cancers in patients from whom the biopsies were obtained. This analysis will be 






Photodynamic Therapy for Cutaneous Squamous Cell Carcinoma In-Situ 
 
62 patients, with a total of 74 unique lesions, who met our inclusion criteria were 
included in the study. Most patients with multiple PDT-treated lesions had them all 
treated during the same office visit, while 2 patients with multiple lesions had initiated 
PDT treatment for each lesion on separate dates. 51 patients had 1 lesion each, 10 
patients had 2 lesions each, and 1 patient had 3 lesions. There were 31 male and 31 
female patients, with an average age of 78 for both male and female patients, ranging 
from ages 52-98 years old for women and 50-94 years old for men. All patients with a 
documented Fitzpatrick phototype had one between 1-3, with 17 patients with phototype 
1, 39 with phototype 2, 4 with phototype 3, and 2 patients whose phototypes were not 
recorded. (Table 1). 
 19 lesions were located on the scalp, 2 were on the ear, 42 were located 
somewhere on the face, 1 was on the neck, 1 was on the chest, 5 were located on the 
upper extremities, and 4 were located on the lower extremities (Table 2).	38 lesions were 
treated with only 1 cycle of PDT at this practice, 26 were treated with 2 cycles, and 10 
lesions required treatment with more than 2 cycles in total (Table 3). However, many of 
the subsequent treatments occurred much later or were in response to recurrences. For 
instance, of the lesions that received 2 cycles of PDT, 2 of those received their second 










Chest or extremities 10 
Table 2. Lesion sites 
  
Number of patients: 62  Number of patients with separate lesions 
treated at the same time with PDT: 
9 
Number of lesions: 74  Number of patients with separate lesions 
treated at separate times with PDT: 
2 
        
Female 31   Male 31   
        
Age    Age    
50-59 3   50-59 4   
60-69 8   60-69 4   
70-79 3   70-79 7   
80-89 10   80-89 13   
>=90 7   >=90 3   
        
Age range 52-98   Age range 50-94   
        
        






        
Fitzpatrick 
phototypes: 
      
1 17       
2 39       
3 4       




Lesions treated with 1 cycle of PDT (prior to any recurrence): 38 
Lesions treated with 2 cycles of PDT: 26 
Lesions treated with 3 or more cycles of PDT: 10 
  
Lesions with complete response after 1 treatment: 39 
Lesions with incomplete or partial response after 1 treatment: 28 
Lesions with minimal or no response after 1 treatment: 4 
Lesions without information on response after 1 treatment: 3 
 
Lesions with recurrences: 9 
Persistent lesions: 7 
Unclear if persistent or recurrent: 1 















Figure 1. Responses to treatment after varying numbers of consecutive PDT sessions. 
Consecutive PDT sessions here refer to all PDT sessions occurring with a <1yr gap 
following the previous PDT session, prior to any recurrences that may have occurred. 





























































































Mean follow-up time for lesions was 12.4 months, ranging from 15 days to 36.9 
months, with standard deviation of 11.7 months. Months are defined as lasting exactly 30 
days for this work. 
For convenience, the term consecutive will be used to refer to treatments that 
occurred within 1 year of the previous treatment and did not occur after a recurrence or 
other form of treatment. 41 lesions received 1 treatment, 28 received 2 treatments, 3 
received 3 treatments 1 received 4 treatments, and 1 received 6 treatments (Figure 1). Of 
the 41 lesions that only received 1 treatment prior to any recurrence if a recurrence 
occurred, 83% (33/40) had a complete response to the treatment, 17% (7/40) did not have 
a complete response, and 1 lesion did not have documentation in the medical record of 
the type of response to treatment. For 28 lesions receiving 2 consecutive treatments of 
PDT, 83% (19/23) had a complete response, 17% (4/23) did not have a complete 
response, and 5 did not have a type of response documented. There is no statistically 
significant difference between complete response rates from 1 PDT treatment and 2 PDT 
treatments, with a p-value=1.0 according to Fisher’s exact test with a 2x2 contingency 
table (Figure 2). The remainder are 3 lesions that received 3 consecutive treatments, 1 
lesion that received 4 consecutive treatments, and 1 lesion that received 6 consecutive 
treatments. All of these had complete responses. Overall, 83% (52/63) of lesions had a 
documented complete response with 1-2 cycles of PDT. (Figure 1). 
Of all the lesions that had documentation on their response to initial PDT 
treatment, 55% (39/71) of lesions had a complete response after 1 PDT cycle, 39.4% 
(28/71) had a partial response after 1 cycle, and 5.6% (4/71) lesions had minimal 




treatment were treated with an additional PDT session despite not having a recurrence in 
the interim. 3 lesions in 3 different patients did not have sufficient information in their 
medical record for us to determine the response to initial PDT, but 2 of them received a 
second PDT treatment had had complete responses to that and the other patient returned 1 
year later to receive Mohs surgery on this lesion site. Of the lesions that were 
documented to not have a complete response after 1 cycle of PDT, 1 lesion was treated 
with Mohs surgery, 3 have documentation suggesting that eventually the lesion resolved 
without further treatment, 2 received no further treatment or follow-up after the initial 
follow-up assessment, 1 had no further treatment and no further documentation regarding 
status of the lesion site (partly due to a patient request limiting the exam), and 25 patients 
then underwent a second round of PDT. 5 of these patients did not return for follow-up 
after the second PDT session, and 65% (13/20) of those who did had a complete response 
after 2 rounds of PDT. Of the 7 that did not have a complete response even after 2 rounds 



















Figure 3. Initial treatment response for all lesions. % of all lesions with documented 








1 treatment 33 7 40 
2 treatments 19 4 23 

















 A logistic regression model for complete response to initial PDT treatment 
analyzing various patient, lesion, and treatment factors was found to be statistically 
significant. The pseudo R2, which measures goodness of fit and generally ranges from 0 
to 1, was 0.5629 for the model. The factors that were significantly associated with a 
complete response after initial PDT treatment were age and large size. A lesion was 
considered large if it had any size measurements of at least 2cm, appeared to be larger 
than 2cm in clinical photos when measurements were not available, and/or was described 
as “large” in a note without specific measurements being given. The odds ratio of 
0.0186913 for lesions of large size to have a complete initial response indicates that all 
else equal, lesions that are large have significantly worse odds to have a complete initial 
response than lesions that are not. The odds ratio of complete initial response and age is 
also less than 1, which means that increasing age is negatively correlated with likelihood 
of a complete response after initial PDT treatment. Other factor variables, such as sex, 
phototype, presence of clinical residual lesion during treatment, lesion site, occlusion, 
incubation time, presence of erythema, and presence of pain, were not found to be 
statistically significant, and the odds ratios of certain skin types and lesion sites were 
empty due to insufficient data points for those. By nature, one variable in each qualitative 







Likelihood of complete response after first PDT treatment  
Pseudo R2 for overall regression model 0.5629  
P-value for overall regression model <0.0001  
    
Independent variable Odds ratio P-value 95% C.I. 
Male sex 1.21434 0.871 .1155304, 
12.76392 
Age .9071233 0.038 .8271304, 
.9948524 
Fitzpatrick phototype   
1 (dummy variable)   
2 1.73871 0.660 .147573, 
20.48553 
3 1 (empty)   
    
Presence of clinical residual lesion 1.534601 0.707 .1648968, 
14.28167 
Large size .0186913 0.014 .0007888, 
.4429009 
Lesion site    
Scalp (dummy variable)   
Ear 1 (empty)   
Face 4.794044 0.224 .3827114, 
60.0527 
Neck 1 (empty)   
Chest or extremities 4.314282 0.498 .0626494, 
297.0982 
    
Occlusion during incubation 5.30028 0.264 .28346, 
99.10734 
Incubation time (hours) 3.338785 0.228 .4693498, 
23.75091 
Presence of erythema 2.909452 0.367 .2854477, 
29.65485 
Presence of pain 1.834726 0.635 .1502722, 
22.40081 




Patients’ reports of side-effects of pain and erythema were significantly correlated 
with incubation time and with presence of erythema or pain, respectively. The logistic 
regression for pain as a dependent variable had a P-value of <0.0001 and pseudo R2 of 
0.5130 for the overall model (Table 5). The logistic regression for erythema as a 
dependent variable had a P-value of 0.0006 and pseudo R2 of 0.3855 (Table 6). 
Incubation time in hours with ALA had a statistically significant relationship with both 
pain and erythema, with an odds ratio of 11.19503 with pain and of 4.110301 with 
erythema, meaning that longer incubation times are likely to cause increased pain and 
erythema. Pain and erythema also appears to correlate positively and significantly with 
one another, with presence of erythema as a factor variable having an odds ratio of 
35.4397 with pain as the dependent variable, and presence of pain as a factor variable 
having an odds ratio of erythema of 8.384352. In the logistic regression model for pain as 
a dependent variable, age approaches near significance as a factor variable, with a p-
value of 0.093 and odds ratio of .9252411. The factor variables of sex, age, phototype, 
presence of clinical residual lesion during treatment, large size, lesion site, and occlusion 







Presence of pain as a side-effect  
Pseudo R2 for overall regression model 0.5130  
P-value for overall regression model <0.0001  
    
Independent variable Odds ratio P-value 95% C.I. 
Male sex .6731383 0.706 .0858131, 
5.280255 
Age .9252411 0.093 .8449507, 
1.013161 
Fitzpatrick phototype   
1 (dummy variable)   
2 1.037243 0.977  .0862991, 
12.46679 
3 1 (empty)   
    
Presence of clinical residual lesion 10.00121 0.213  .3990067, 
61.14648 
Large size .5972647 0.630 .073196, 
4.873563 
Lesion site    
Scalp (dummy variable)   
Ear 1 (empty)   
Face 1.313394 0.805 .1512651, 
11.40384 
Neck 1 (empty)   
Chest or extremities 2.001625 0.725 .0421828, 
94.97954 
    
Occlusion during incubation 4.939418 0.112  .5137863, 
565.6868 
Incubation time (hours) 11.19503 0.032 1.230876, 
101.8207 
Presence of erythema 35.4397 0.040  






Presence of erythema as a side-effect  
Pseudo R2 for overall regression model 0.3855  
P-value for overall regression model 0.0006  
    
Independent variable Odds ratio P-value 95% C.I. 
Male sex 1.148807 0.886 .1724624, 
7.652436 
Age 1.016078 0.597 .9577616, 
1.077945 
Fitzpatrick phototype   
1 (dummy variable)   
2 .2336373 .2198271 .0369534, 
1.477166 
3 1 (empty)   
    
Presence of clinical residual lesion .6247012 .5873517 .0989378, 
3.944414 
Large size 1.103538 0.914 .1843299, 
6.606615 
Lesion site    
Scalp (dummy variable)   
Ear 1 (empty)   
Face 3.179493 0.211 .5185188, 
19.49626 
Neck 1 (empty)   
Chest or extremities 2.166933 0.587 .1330546, 
35.29075 
    
Occlusion during incubation .8318299 0.853 .1194089, 
5.79472 
Incubation time (hours) 4.110301 0.033 1.120249, 
15.08108 
Presence of pain 8.384352 0.018 1.436711, 
48.92936 





 Survival analysis was limited by the fact that most patients did not have 
systematic follow up. Patients without evidence of disease were often discharged after a 
few months, since generally patients would follow-up with their primary dermatologists 
in the long-term rather than with a specialized dermatologic surgery clinic. However, 
patients with late recurrence were often referred back to Yale Dermatologic Surgery for 
evaluation. In this way, a large proportion of recurrences are likely to be detected in our 
study. Survival groups here refer to the number of PDT treatments that patients received 
within 1 year of previous treatment, before any recurrence or other treatment for 
persistent disease occurred, and with follow-up data. 
Treated lesion fields had a mean disease-free survival time of 13.379 months 
(standard deviation of 2.0 months, C.I. [9.477, 17.280], 41 observations) if they only 
received 1 consecutive PDT treatment, mean disease-free survival time of 13.590 months 
(standard deviation of 2.3 months, C.I. [9.072, 18.107], 23 observations) if they received 
2 PDT treatments meeting above criteria, and mean disease-free survival time of 0.933 
months (insufficient data points to calculate standard deviation or C.I., 5 observations) 
for >2 consecutive PDT treatments. Once again, months here refer to 30-day intervals 
and not calendar months. The log-rank test revealed a statistically insignificant 
discrepancy between the survival curves for the 1 PDT treatment group and the 2 PDT 
treatments group, with a p-value of 0.801. One lesion that received 1 consecutive PDT 
treatment did not have data on initial treatment response but did have usable data for the 
survival function. (Figure 4). 
Following 1 consecutive treatment, there were 12 failures total including 4 




for 2 consecutive treatments, there were 10 failures total including 6 documented 
recurrences with a recurrence rate of 32% (6/19), and 13 censored entries. None of the 
lesions receiving >2 consecutive PDT treatments were documented to have a recurrence, 
and apart from 2 lesions in this group with follow-up length of 33.6 months, the rest all 












Figure 4. Kaplan-Meier survival functions for 1, 2, and >2 consecutive PDT treatments 
with follow-up data. Blue represents the group that received 1 treatment, green represents 
2 PDT treatments, and red represents >2 consecutive PDT treatments. Only 5 lesions 





















Mutation Burden Analysis 
Since PDT treats the field surrounding a cancerous lesion as well as the lesion 
itself, it may have a clinical role in treating field cancerization and preventing further 
development of malignant cells. However, in the absence of visibly abnormal lesions, 
clinical observation of field cancerization may not be possible. In order to better quantify 
the risk posed by field cancerization in patients’ skin, a method using sequencing and 
mutation burden analysis could prove useful. 
A necessary step for mutation burden analysis would be collection of relevant 
DNA samples for testing. Punch biopsy is a method that is often used by dermatologists 
to collect skin samples and DNA can be extracted from these skin samples. DNA yield 
depends upon number and size of biopsies and DNA purification method. 1mm diameter 
punch biopsies fail to consistently yield sufficient DNA (≧1µg) for our study. Phenol-
chloroform extraction led to higher DNA yields than the QIAamp® kit. Individual 2mm 
punch biopsies purified with phenol-chloroform extraction provided high DNA yields 
while minimizing required biopsy material. As expected, DNA yields correlated 
positively with punch biopsy size and the number of punch biopsies used in a single 
sample. However, even two 2mm punch biopsies when purified with the QIAamp® kit, 
with an average yield of 2.2µg and SD of 0.29 for 2 samples, yielded less DNA than one 
2mm punch biopsy when using phenol-chloroform, with an average yield of 3.6µg and 
SD of 2.3 for 7 samples. Three 2mm punch biopsies when purified with phenol-





In order to sequence DNA samples for the mutation burden analysis, amplicons 
including target sequences must first be generated. Initially, long-range PCR was 
attempted but this proved unsuccessful. PCR results of more than 20 samples shows that 
PCR amplification can occur fairly reliably up to slightly over 1.5kb in amplicon size 
based on visual confirmation of gel electrophoresis, but PCR amplification of amplicon 
sizes larger than that are not consistently successful. With some variation between 
samples, PCR amplification of amplicon lengths around 1.5kb or less could sometimes be 
achieved with 30 cycles or fewer, but amplification at higher amplicon lengths did not 
yield visible bands at the right size even with 35 cycles or more. (Figure 6). 
Subsequently, we attempted a different strategy using an extension-ligation 
system marketed by Illumina®. Using Illumina, Inc.’s Design Studio ® software, primers 
targeting the 5’ UTR and CDS of TP53, Hras, Nras, Kras, CDKN2a, Notch1, Notch2, 
Notch3, Fat1, Fgfr3, Knstrn, Braf, and VHL (control gene), along with 10bp of intron 
padding around these sequences, was generated. Extra padding was also designed around 
important regions, such as regions with documented mutations in literature. These 
primers should promote the amplification of 250bp amplicons and cover both DNA 
strands of each target region utilizing dual-pool design. The cumulative target size was 
59,547bp with 2 x 394 distinct amplicons. The design ultimately included 3 gaps totaling 
a length of 276bp. 
The first sequencing run generated with 20 skin samples from 8 skin cancer 
patients yielded a total sequence of 1.54e11 bp with a quality score of 72.26%. Total 




sample was 5.57e9 bp. Dividing this last number by the total sequencing target size 
(59,547 bp)leads to an average of 93,500-fold coverage per sample.  






























Figure 6. PCR results from purified genomic DNA extracted from human skin samples, 
as an indicator of DNA quality. PCR amplification occurs fairly reliably up to 1.5kb 
amplicon size, but did not work at >3kb amplicon sizes. A. Results of 30 and 26 cycles of 
PCR, Hras primer set with expected amplicon size of 415bp, and 5ng template DNA 
(except for 3.92ng for 4B and 1.5ng for 5A). B. PCR results with 35 cycles, TP53 primer 
set with expected band sizes of 3567bp (A), 3727bp (B), 2912bp (C), and 5ng template 
DNA. C. PCR results with 30 cycles, TP53 primer set with expected band size 1536bp, 







 While the complete response rate of 55% after 1 cycle of PDT may seem a bit 
low, 83% (52/63) of lesions had a documented complete response with 1-2 cycles of 
PDT. Following an incomplete initial response to PDT, only 65% (13/20) of lesions will 
exhibit a complete response to a second round of PDT, suggesting diminishing marginal 
returns with additional sessions of PDT. In contrast, 83% (19/23) of all patients with 2 
consecutive PDT treatments had a complete response. This discrepancy is likely due to 
patients not being randomly assigned to receive 1 or 2 cycles of PDT, but rather many 
patients who received 2 cycles of PDT did so because their lesion did not completely 
resolve after receiving 1 cycle of PDT. Furthermore, the difference in complete response 
rates after 1 session of PDT versus 2 sessions of PDT was not statistically significant, and 
the response rates themselves were not different. Therefore, initially starting a protocol 
involving 2 PDT treatments may not be beneficial compared to initially starting a 
protocol involving 1 PDT treatment, and given contemporary concerns over healthcare 
costs as well as patient convenience, it may be worthwhile to initiate PDT with only 1 
planned treatment and then decide whether to continue with more PDT sessions based on 
the follow-up assessment. 
 Most of the literature published on PDT treatment for SCCIS involves multiples 
PDT treatments, with reported complete response rates ranging from 75% to 100%. The 
most relevant comparison may be our 83% complete response rate following 1-2 sessions 
of PDT, which is within the range described by the literature. Complete response rate 
after initial treatment does not appear to be an appropriate comparison since most other 




more. Complete response rate after 1-2 sessions of PDT appears comparable to 
imiquimod’s reported 75-93%[43, 44] and 5-FU’s 67-92% [43, 45]. Mohs surgery 
certainly exceeds PDT’s complete response rate, since the surgery is designed to continue 
until reaching 100% complete response rate, so if PDT is chosen instead of surgery there 
is typically some reason other than response rate and considering this study did not find a 
different response rate, it should not impact that decision.  
 Clinically, it is unlikely that patients would receive more than 2 cycles of PDT for 
a persistent lesion unless there was some contraindication for definitive treatment such as 
surgery, so evaluation of the efficacy of >2 cycles of PDT is challenging. Usually the 
cycles would be spaced very far apart since they were not offered as part of the same 
treatment sequence, but rather for a recurrence later in time or for another lesion in a 
similar region. In our case, we had insufficient data on lesions receiving >2 cycles of 
PDT to draw substantial conclusions. 
 This study was fairly unique in the sense that patients were treated with blue light 
rather than red light, which has a shorter wavelength and in theory should more 
efficiently generate ROS and free radicals. The downside is that blue light is less able to 
penetrate deeply into tissue than red light, but the hope is that the superficial nature of 
SCCIS would lessen the potential negative impact. 
 The logistic regression models for response after first PDT treatment and PDT 
side-effects had relatively high pseudo R2 values and low p-values, suggesting that the 
models fit the data fairly well and are likely significant. In contrast to linear regression 
models, where R2 (without the “pseudo” in front) more directly indicates the amount of 




do not obey the same assumptions regarding homogeneity of standard error values at 
different points in the model, and thus the interpretation of the pseudo R2 and the 
appropriate method of calculating pseudo R2 can be controversial. Furthermore, while R2 
is easier to interpret because its range is constrained between [0,1], under certain 
circumstances the lower bound of pseudo R2 is above 0 and the upper bound is below 1. 
Another complication of regression models is that data points missing any of the 
variables are completely excluded from the calculation of the model. While this may be 
more justifiable than the alternative method of systematically replacing missing data with 
certain values, it does mean that collecting more variables may lead to greater loss of data 
and precision, since the more variables are collected, the greater the likelihood that any 
data point would be missing some factor variable data. 
In terms of precision and statistical significance, our study involved a fairly small 
sample size, especially in comparison to the number of variables that we were analyzing, 
which made statistical significance less likely. Given that we had some factor variables 
that were not statistically significant but close to statistical significance, further study 
with larger sample sizes may lead to more statistically significant findings. 
Regression models also run the risk that strong correlation to an independent 
variable may actually indicate a relationship with a confounding factor left out of the 
model. 
For complete response after initial PDT treatment, increasing age and large size 
were found to significantly correlate against complete response. Normally, if a treatment 
is less likely to be successful, the recommendation may be to preferentially pursue other 




contraindications to surgery, which is often the reason why PDT is pursued in the first 
place. Since PDT has fewer side-effects than surgery, especially in this population, it may 
be worth pursuing as initial treatment anyway. 
 Side-effects of pain and erythema were significantly correlated with 
photosensitizer incubation time and with the presence of each other. While regression 
models indicate correlation and not causation, incubation times were chosen by the 
provider and possibly influenced by scheduling circumstances of the patient, but are 
otherwise unlikely to have been influenced by anything that could have served as a 
confounding variable for pain and erythema, and since the side-effects of pain and 
erythema strictly occur temporally after incubation time has already been fixed, it is 
likely that the relationship is one of causality and not merely correlation. Since incubation 
occurs because ALA needs time for absorption and metabolism into the photosensitizer 
PPIX, it makes theoretical sense for the side-effects of PDT to be caused by this step in 
the treatment procedure. The significant correlation between the presence of one side-
effect and the other is not counterintuitive, since they are both occurring as a result of the 
same treatment. Although at first glance it might seem surprising that the odds ratios are 
not equal between that of pain as a factor variable and erythema as the dependent variable 
and vice versa, there are many cases of highly correlated conditions that would not have 
the same odds ratio as that of the converse case, such as with fair skin and skin cancer 
diagnosis or with pregnancy status and female sex. 
 Since the main goal of PDT treatment is clearance of SCCIS and prevention of 
recurrence, I do not think that incubation time should be adjusted with the purpose of 




 In terms of the disease-free survival analysis, the main difficulty is that the true 
recurrence rate is probably too low in relation to our follow-up lengths for us to reliably 
model the survival function. As a carcinoma in-situ, SCCIS is not as aggressive as 
invasive SCC, it may be less likely to recur and its recurrence may take longer. Previous 
studies that looked specifically at long-term recurrence rates had average follow-up 
lengths of 43.5-60 months, with recurrence rates of 11.6%, 54%, and 57% [105, 106, 
108], which shows fairly large variation. Our recurrence rates of 12% (4/33) for 1 PDT 
treatment and 32% (6/19) for 2 PDT treatments are on the lower end of the reported 
range, but our follow-up time of 15 days to 37 months is also much shorter. 
 Even so, surgery has lower reported recurrence rates of 4.6%-8.3%.[39-42] From 
the perspective of preventing recurrences, surgery is clearly the superior treatment 
method, which means that if PDT is being utilized instead of surgery, it is for other 
reasons that outweigh the consideration of recurrence rate. This study highlights the fact 
that PDT treatment of SCCIS may have a recurrence rate as high as 1 in 3, and this must 
be considered when deciding between PDT and other forms of treatment such as surgery. 
Other than lesion size and patient age, this study does not identify specific factors 
correlated with PDT response, and the clinical considerations that ultimately lead to 
choosing PDT over surgery should remain unchanged. 
Additionally, one challenge of this being a retrospective study is the lack of 
systematic follow up. This means that in practice, patients may only visit the clinic for 
procedures and short-term follow-up, and then resume follow-ups with their primary 
dermatologist, with referrals back to the dermatological surgery clinic in case of 




disease-free survival intervals are likely shorter than the true disease-free survival 
intervals, since patients who remain disease-free may never return. Paradoxically, it is 
possible that some of the patients with the longest disease-free survival intervals may 
have the shortest documented disease-free survival lengths based on follow-up visits. 
The survival curves that I obtained for 1 consecutive PDT treatment versus 2 
consecutive PDT treatments were not statistically significant, had very similar mean 
disease-free survival times, and even appeared to overlap visually. Therefore, additional 
PDT treatments for the purpose of preventing future disease, or PDT treatments “just in 
case” after a complete response to initial treatment, are not clinically indicated and may 
lead to unnecessary discomfort and usage of healthcare resources. 
To summarize, since 1 consecutive cycle of PDT and 2 consecutive cycles of PDT 
have similar complete response rates and disease-free survival functions, an additional 
cycle of PDT is not indicated unless complete response was not achieved following initial 
PDT treatment. 65% (13/20) of lesions that did not have a complete response to initial 
treatment displayed a complete response to a second round of PDT, suggesting there is 
some utility to continuing PDT after a failed treatment. However, it is between the patient 
and the doctor at that point to decide whether to continue PDT or pursue other treatment 
modalities. Since this study does not significantly change current knowledge of PDT’s 
response and recurrence rates, decisions between PDT and surgery should depend on the 
existing decision-making variables of patient preference, patient-specific factors that 
make him a poor surgical candidate, and lesion-specific factors that contraindicate 




of the factors such as increasing age and large lesion size that make surgery a less 
desirable choice may also decrease the effectiveness of PDT. 
 The project analyzing mutation burden in normal sun-damaged skin is still in 
process, and we have yet to perform the sequencing analysis. In the future, the results of 
this project could potentially be used to identify an individual patients’ subsequent risk of 
developing skin cancer based on mutation burden, with prospective determination of 
mutation burden with clinical follow-up to assess cancer development. Clinical 
application of this information may also allow more appropriate screening and preventive 
treatment in high-risk patients. Punch biopsy, the method used to obtain DNA, is already 
commonly used in dermatology clinics and is therefore readily available. Mutation 
burden analysis in individual patients may also facilitate the monitoring of clinical 
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